Novitas says Pacific Edge’s CxBladder tests are ‘not payable’

Novitas says Pacific Edge’s CxBladder tests are ‘not payable’
The company can continue to apply for renewed coverage. (Image: Pacific Edge)
Rebecca Howard
The long-awaited draft Local Coverage Determination from Novitas is not good news for Pacific Edge’s US business. According to the determination (LCD), “CxBladder tests are not reasonable and necessary to support positive outcomes in the management of bladder cancer and, therefore, are not payable”.In June 2023, Pacific Edge confirmed that the LCD from Novitas — its Medicare administrative contractor — meant its flagship Cxbladder test for bladder cancer didn’t meet the threshold required for coverage un...

More Markets

NZ sharemarket down 0.2% as Trump retakes office
Markets Market Close

NZ sharemarket down 0.2% as Trump retakes office

The S&P/NZX 50 Index closed at 13.052.9, down 35.41 points or 0.27%.

Graham Skellern 21 Jan 2025
Rua Bioscience psilocybin study targets meth addiction
Markets

Rua Bioscience psilocybin study targets meth addiction

The ‘preparation step’ will be followed by an ‘experiential session’ with the mushroom.

Gregor Thompson 21 Jan 2025
Jarden sees Mercury, Genesis upside
Markets

Jarden sees Mercury, Genesis upside

Energy margin data points to earnings upgrades for both gen-tailers.

Pattrick Smellie 21 Jan 2025
Cooks Coffee continues strong sales growth
Retail

Cooks Coffee continues strong sales growth

The sales growth comes at a time of rapid expansion for the firm.

Staff reporters 21 Jan 2025